Trials / Completed
CompletedNCT05230290
Clinical Study of KD6001 in Advanced Solid Tumours
Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and clinical activity of KD6001 as treatment for participants with advanced solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | KD6001 Injection | Solution for intravenous injection |
Timeline
- Start date
- 2020-09-10
- Primary completion
- 2022-07-20
- Completion
- 2022-07-26
- First posted
- 2022-02-08
- Last updated
- 2023-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05230290. Inclusion in this directory is not an endorsement.